<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo>, cerebrospinal fluid analysis (CSF) is predominantly performed to exclude <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e> and to perform a risk assessment in dementive disorders by measurement of tau proteins and amyloid beta <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>However, large scale data on basic findings of CSF routine parameters are generally lacking </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of the study was to define a <z:mpath ids='MPATH_458'>normal</z:mpath> reference spectrum of routine CSF parameters in <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Routine CSF parameters (white cell count, <z:chebi fb="4" ids="24996">lactate</z:chebi> and albumin concentrations, CSF/serum quotients of albumin (Q (alb)), IgG, IgA, IgM, and oligoclonal IgG bands (OCB)) were retrospectively analyzed in an academic research setting </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 765 patients (<z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> <z:hpo ids='HP_0000726'>dementia</z:hpo> (PDD), vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD), <z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">frontotemporal lobar degeneration</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>), <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (PSP), multisystem <z:mpath ids='MPATH_127'>atrophy</z:mpath> (MSA), <z:e sem="disease" ids="C0085084" disease_type="Disease or Syndrome" abbrv="">motor neuron diseases</z:e> (MND), spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> (SCA), <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>)) and non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> control groups including a group of patients with <z:e sem="disease" ids="C0026848" disease_type="Disease or Syndrome" abbrv="">muscular disorders</z:e> (MD) </plain></SENT>
<SENT sid="5" pm="."><plain>The main outcome measures included statistical analyses of routine CSF parameters </plain></SENT>
<SENT sid="6" pm="."><plain>Mildly elevated Q (alb) were found in a small percentage of nearly <z:hpo ids='HP_0000001'>all</z:hpo> subgroups and in a higher proportion of patients with PSP, MSA, VD, PDD, and MND </plain></SENT>
<SENT sid="7" pm="."><plain>With the exception of 1 MND patient, no intrathecal Ig synthesis was observed </plain></SENT>
<SENT sid="8" pm="."><plain>Isolated OCBs in CSF were sometimes found in patients with <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> without elevated cell counts; <z:chebi fb="4" ids="24996">lactate</z:chebi> levels were always <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>A slightly elevated Q (alb) was observed in a subgroup of patients with <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> and does not exclude the diagnosis </plain></SENT>
<SENT sid="10" pm="."><plain>Extensive elevation of routine parameters is not characteristic and should encourage a re-evaluation of the clinical diagnosis </plain></SENT>
</text></document>